| Dr Miranda Adanna Ewelukwa, MD | |
|
1327 Lake Pointe Pkwy Ste 416, Sugar Land, TX 77478-3499 | |
| (281) 494-0050 | |
| Not Available |
| Full Name | Dr Miranda Adanna Ewelukwa |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 11 Years |
| Location | 1327 Lake Pointe Pkwy Ste 416, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174967756 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0900X | Dermatology - Dermatopathology | R7918 (Texas) | Primary |
| 207N00000X | Dermatology | R7918 (Texas) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oliver Street 5.01(a) Inc | 0042464125 | 141 |
News Archive
The resources developed for an innovative collaborative model of dementia care, which reduces emergency room and hospital visits and improves the quality of care for those with dementia, are now available to institutions, clinicians and caregivers around the globe with the establishment of the Aging Brain Care Program.
A new, Yale-led study examines shifts in fertility behaviors among Generation X women in the United States - those born between 1965-1982 - compared to their Baby Boomer counterparts, and explores whether the fertility of college-educated women is increasing more quickly across cohorts in Generation X than the fertility of their less educated counterparts.
The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study period in this trial. This important achievement in the Diamyd® Phase III program will now be followed by an intense period where the data will be compiled from the more than 60 clinics throughout Europe and from the central laboratory.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint.
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease.
› Verified 6 days ago
| Entity Name | Oliver Street 5.01(a) Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457695413 PECOS PAC ID: 0042464125 Enrollment ID: O20130128000189 |
News Archive
The resources developed for an innovative collaborative model of dementia care, which reduces emergency room and hospital visits and improves the quality of care for those with dementia, are now available to institutions, clinicians and caregivers around the globe with the establishment of the Aging Brain Care Program.
A new, Yale-led study examines shifts in fertility behaviors among Generation X women in the United States - those born between 1965-1982 - compared to their Baby Boomer counterparts, and explores whether the fertility of college-educated women is increasing more quickly across cohorts in Generation X than the fertility of their less educated counterparts.
The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study period in this trial. This important achievement in the Diamyd® Phase III program will now be followed by an intense period where the data will be compiled from the more than 60 clinics throughout Europe and from the central laboratory.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint.
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Miranda Adanna Ewelukwa, MD 5310 Harvest Hill Rd Ste 290, Dallas, TX 75230-5826 Ph: (214) 420-0650 | Dr Miranda Adanna Ewelukwa, MD 1327 Lake Pointe Pkwy Ste 416, Sugar Land, TX 77478-3499 Ph: (281) 494-0050 |
News Archive
The resources developed for an innovative collaborative model of dementia care, which reduces emergency room and hospital visits and improves the quality of care for those with dementia, are now available to institutions, clinicians and caregivers around the globe with the establishment of the Aging Brain Care Program.
A new, Yale-led study examines shifts in fertility behaviors among Generation X women in the United States - those born between 1965-1982 - compared to their Baby Boomer counterparts, and explores whether the fertility of college-educated women is increasing more quickly across cohorts in Generation X than the fertility of their less educated counterparts.
The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study period in this trial. This important achievement in the Diamyd® Phase III program will now be followed by an intense period where the data will be compiled from the more than 60 clinics throughout Europe and from the central laboratory.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint.
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease.
› Verified 6 days ago
Dr. Stephanie Florez-pollack, MD Dermatology Medicare: Medicare Enrolled Practice Location: 7616 Branford Pl Ste 240, Sugar Land, TX 77479 Phone: 281-240-4313 | |
Dr. Sunaina Bhuchar Likhari, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3533 Town Center Blvd S Ste 200, Sugar Land, TX 77479 Phone: 812-912-3425 | |
Dr. Keith E Schulze, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 15400 Southwest Fwy, Suite 150, Sugar Land, TX 77478 Phone: 281-980-6647 Fax: 281-980-6650 | |
Dr. Lauren Allyson Snitzer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1327 Lake Pointe Pkwy Ste 416, Sugar Land, TX 77478 Phone: 281-494-0050 Fax: 281-494-0075 | |
Dr. Pamela Margaret Carr, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1111 Highway 6 Ste 160, Sugar Land, TX 77478 Phone: 281-494-0034 Fax: 281-494-0066 | |
Dr. Mushtaq Ahmad Khan, Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1410 N Horseshoe Dr, Sugar Land, TX 77478 Phone: 281-302-5756 Fax: 281-990-6356 |